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ABSTRACT
Objectives To compare prevalence and types of
dispensing errors and pharmacists’ labelling
enhancements, for prescriptions transmitted
electronically versus paper prescriptions.
Design Naturalistic stepped wedge study.
Setting 15 English community pharmacies.
Intervention Electronic transmission of
prescriptions between prescriber and pharmacy.
Main outcome measures Prevalence of
labelling errors, content errors and labelling
enhancements (beneficial additions to the
instructions), as identified by researchers visiting
each pharmacy.
Results Overall, we identified labelling errors in
5.4% of 16 357 dispensed items, and content
errors in 1.4%; enhancements were made for
13.6%. Pharmacists also edited the label for a
further 21.9% of electronically transmitted items.
Electronically transmitted prescriptions had a
higher prevalence of labelling errors (7.4% of
3733 items) than other prescriptions (4.8% of
12 624); OR 1.46 (95% CI 1.21 to 1.76). There
was no difference for content errors or
enhancements. The increase in labelling errors
was mainly accounted for by errors (mainly at
one pharmacy) involving omission of the
indication, where specified by the prescriber,
from the label. A sensitivity analysis in which
these cases (n=158) were not considered errors
revealed no remaining difference between
prescription types.
Conclusions We identified a higher prevalence
of labelling errors for items transmitted
electronically, but this was predominantly
accounted for by local practice in a single
pharmacy, independent of prescription type.
Community pharmacists made labelling
enhancements to about one in seven dispensed
items, whether electronically transmitted or not.
Community pharmacists, prescribers, professional
bodies and software providers should work
together to agree how items should be
dispensed and labelled to best reap the benefits
of electronically transmitted prescriptions.
Community pharmacists need to ensure their
computer systems are promptly updated to help
reduce errors.
INTRODUCTION
Studies from the UK1–4 and elsewhere5 6
have highlighted the prevalence of medica-
tion errors in primary care. Internationally,
estimates of dispensing error rates in com-
munity pharmacies vary from 0.04%1 to
24%5 of dispensed items, the wide vari-
ation at least partly due to differences in
methods and definitions. Dispensing
errors may involve the wrong product
being dispensed (‘content errors’) or the
wrong information being printed on the
dispensing label (‘labelling errors’). We
previously used a research pharmacist to
identify errors in nearly 3000 dispensed
items in 11 community pharmacies in
England and Wales.2 A content error was
identified in 1.7% of dispensed items and
a labelling error in 1.6%.
A commonly advocated approach to
reducing dispensing errors is to make
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greater use of information technology such as compu-
terised prescribing and the electronic transmission of
prescriptions to community pharmacies for dispens-
ing.7 8 While computerised prescribing has been com-
monplace in UK primary care for some time, until
recently there has been no system for transferring pre-
scriptions electronically to community pharmacies,
and prescriptions were, instead, printed out and taken
by hand. Within England, the introduction of the
Electronic Prescription Service (EPS) began in 2005.
This occurred in two phases: EPS Release 1 (EPSR1)
and EPS Release 2 (EPSR2). EPSR1 was intended to
test the infrastructure needed for EPSR2 in which
electronic prescriptions are digitally signed by the pre-
scriber and transmitted electronically to a nominated
community pharmacy of the patient’s choice. The first
sites went live with EPSR2 in July 2009. Box 1
presents characteristics of each prescription type.
As well as increased efficiency, the expected benefits
of EPSR2 included gains in patient safety, as theoretic-
ally there is no need for pharmacy staff to re-enter a
prescriber’s instructions or interpret illegible prescrip-
tions, thereby reducing the risk of errors involving
transcription of information onto the dispensing label.
However, it is not yet known whether these potential
benefits have been realised. Internationally, most
studies of electronic prescriptions in the community
setting have focused on prescribing;9 10 there are few
studies of the impact on dispensing errors. In a con-
trolled before and after study, Moniz et al11 reported
a reduction in the prevalence of dispensing errors
from 3.1% to 1.8% of prescriptions when electronic
transmission was added to a well-established elec-
tronic prescribing system in US outpatient clinics.
However, the study was based on identifying discrep-
ancies between electronic prescription records and
electronic dispensing records; there was no check of
dispensed items. Additionally, while there is a consid-
erable literature on the interventions made by commu-
nity pharmacists to resolve prescribing errors on
paper-based and electronic prescriptions,12 13 little is
known about other additional enhancements that
community pharmacists make to clarify or enhance
the prescriber’s instructions on dispensing labels, and
how these may change with the introduction of an
electronic transmission system such as EPSR2.
Our objectives were to compare for EPSR2 versus
non-EPSR2 prescriptions: (1) the prevalence and
types of labelling and content errors in community
pharmacies and (2) the prevalence of labelling
enhancements made by pharmacy staff.
METHODS
Setting
The study took place in a sample of English commu-
nity pharmacies; the vast majority of prescriptions dis-
pensed in such pharmacies were prescriptions from
local general practitioners (GP) on standard National
Health Service (NHS) prescription forms. We were
interested in the three main types of NHS prescription
(box 1).
Study design and sample size
The study was originally planned as a controlled
before-and-after study. The prevalence of labelling
errors was our primary outcome measure as these
were anticipated to be reduced by EPSR2. The preva-
lence of content errors and labelling enhancements
were secondary outcome measures. Our main com-
parison of interest was items prescribed using EPSR2
versus those prescribed on all other types of prescrip-
tion (non-EPS and EPSR1). Exploratory work sug-
gested that while EPSR1 prescriptions were computer
generated, the electronic transmission functionality
was rarely used and they were almost always taken by
hand to the pharmacy; these were therefore grouped
with non-EPS prescriptions for analysis. Our sample
size was calculated based on the original controlled
before-and-after design. We assumed a baseline
Box 1 National Health Service (NHS) prescriptions
dispensed in English community pharmacies
Non-EPS prescriptions are generally computer generated,
printed onto an NHS prescription form, manually signed
by the prescriber (who may be a medical or non-medical
prescriber), and given to the patient to take to the phar-
macy of their choice. Prescriptions are also occasionally
handwritten directly onto the prescription form.
EPSR1 prescriptions are standard computer-generated
paper prescriptions, manually signed by the prescriber as
above, but with an additional barcode. These are given
to the patient to take to the community pharmacy of
their choice. If the barcode is scanned in an EPS-enabled
pharmacy, an electronic copy of the prescription data can
be downloaded to the pharmacy computer to populate
the patient medication record and dispensing labels;
alternatively the paper prescription can be dispensed as
for a non-EPS prescription.
EPSR2 prescriptions are digitally signed by the prescriber
and transmitted electronically to a nominated community
pharmacy of the patient’s choice. Patients are generally
given a non-essential printed ‘token’ in lieu of a prescrip-
tion, while the legal prescription is transmitted to the
nominated pharmacy via a central server. Community
pharmacies regularly download all prescriptions received.
A barcode on the token can also be used to download
the prescription at a different pharmacy if required.
In each case, one prescription form (or electronic equiva-
lent) can generally include up to about four prescribed
items; patients requiring more than this require more
than one prescription form.
EPSR, Electronic Prescription Service Release.
Original research
630 Franklin BD, et al. BMJ Qual Saf 2014;23:629–638. doi:10.1136/bmjqs-2013-002776
group.bmj.com on January 22, 2018 - Published by http://qualitysafety.bmj.com/Downloaded from 
labelling error rate of 1.6%,2 and anticipated a
minimum 50% relative reduction in the mean label-
ling error rate in the EPS2 pharmacies. Assuming a
reduction in the mean labelling error rate of 10% in
the control group pharmacies, power of 80%, a 1 : 1
ratio of EPSR2:non-EPSR2 prescriptions, and a two-
sided significance level of 5%, 26 pharmacies per
group were required to detect a difference. After
adjustment for clustering by primary care trust (PCT),
assuming an intracluster correlation coefficient of
0.01, and that five pharmacies per PCT would be
recruited, 28 pharmacies per group were required. We
therefore aimed to recruit six PCTs in the EPSR2
group and six in a control group.
When it became apparent that the roll out of
EPSR2 was beyond our control and that it would be
difficult to assess the time point at which ‘after’ mea-
surements should be assessed due to uncertainty about
how quickly pharmacies would become proficient at
using EPSR2, we revised our design to a non-
randomised stepped wedge study. We estimated that
within our existing resources we could collect data in
42 pharmacies, and that we would have 80% power
to capture a change in the prevalence of labelling
errors from 1.6%2 to 1.2% of dispensed items,
(assuming a two-sided significance level of 5%, and
that 200 dispensed items were examined at each of
five data collection visits at each pharmacy site). We
aimed to visit each pharmacy five times at approxi-
mately 3-month intervals, starting before the phar-
macy had gone live with EPSR2.
Recruitment
Originally, it had been planned that EPSR2 would be
launched in two phases of initial implementer pilot
sites based in 17 English PCTs, prior to national roll
out. We approached six PCTs due to be the first to go
live and asked them to identify community pharma-
cies likely to go live with EPSR2 during the period
2009–2011. Pharmacies were approached and
recruited on an on-going basis during this time. When
these original implementation plans changed
nationally, we continued collecting data at recruited
sites even though some did not subsequently imple-
ment EPSR2 during our study period. We therefore
started introducing new community pharmacy sites
that had already started using EPRSR2 in order to
obtain sufficient numbers of EPSR2 prescriptions;
such pharmacies also dispensed non-EPSR2 prescrip-
tions. We extended the data collection period to
include more three-monthly data collection visits to
compensate for having fewer pharmacies, and the
uptake of EPSR2 being slower than expected.
Outcome measures
We initially identified ‘anomalies’ associated with dis-
pensed items, where anomalies were any difference
between the prescription plus any relevant statutory
requirements, and the items dispensed. Anomalies
included beneficial enhancements as well as potential
dispensing errors, and each dispensed item could have
more than one anomaly. Each anomaly was then clas-
sified into one or more of four mutually exclusive cat-
egories, indicated by the four white boxes in figure 1.
We used a definition of a dispensing error devel-
oped with practising pharmacists for use in UK com-
munity pharmacies (box 2);2 this is accompanied by
lists of examples of scenarios which should be
included and excluded as errors. The Royal
Pharmaceutical Society’s Medicines, Ethics and
Practice guide and the British National Formulary
were used as references for statutory requirements and
recommended additional labels, using the versions in
use at the time of data collection. We also developed
definitions for labelling enhancements and for
EPSR2-specific labelling errors as we wished to iden-
tify these separately (box 2). Finally, pilot work
revealed that for EPSR2 prescriptions, community
pharmacy staff often made changes to the prescriber’s
directly transmitted directions to better communicate
these to the patient. Where the original directions did
not constitute a prescribing error, we termed these
‘EPSR2-specific interventions’ and reported these
separately.
Figure 1 Classification of anomalies between prescription and dispensed items (EPSR2, Electronic Prescription Service Release 2).
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Data collection
Data collection methods were based on those used
previously.2 A researcher (pharmacist or pharmacy
technician) examined dispensed items in each phar-
macy and recorded details of any anomalies. To min-
imise impact on pharmacy workflow, we focused on
items previously dispensed and awaiting collection.
However, if necessary to achieve the desired sample,
and if practical, some items were also checked in real
time, immediately after the pharmacist’s final check
and before they were given to the patient. Items dis-
pensed against all types of NHS prescription (box 1)
were included. Controlled drugs, items dispensed in
multicompartment compliance aids and private pre-
scriptions were excluded. Patient counselling was not
observed. Data collection visits were agreed in
advance with the relevant community pharmacist. At
each data point in each pharmacy, we aimed to
examine around 200 dispensed items over a 1 or
2-day period. Where more than 1 day’s data collection
was required to achieve this sample, these were sched-
uled up to 2 weeks apart to allow turnover of dis-
pensed items awaiting collection.
On the first visit to each pharmacy, the researcher
briefed the pharmacy staff regarding the aim of the
study and the data collection methods. Pharmacy staff
were informed that they would be alerted to errors if
the researcher believed they would have a detrimental
impact on the prescription’s recipient, but that errors
would not be reported to employers.
Dispensed items were compared against the pre-
scription and a data collection form completed for
each patient. For any dispensed item with one or
more anomalies, details were recorded. If it was
unclear whether an anomaly was intended or not,
clarification was requested from the pharmacist. For
example, 58 tablets dispensed against a prescription
for 60 tablets could have been due to lack of stock
with the balance to follow, rather than miscounting or
misreading the prescription. If in doubt about any
anomaly, the researcher recorded details for discussion
among the wider team, as below.
Data were collected by four pharmacists and a
senior pharmacy technician. The majority of data (79
of 95 data collection visits; 83%) were collected by
the technician (MR) and/or one of the pharmacists
(SS); these two researchers independently examined
items dispensed for the same 40 patients at the begin-
ning of the study to assess inter-rater reliability. The
other three pharmacists were comprehensively briefed
on methods and definitions, and shadowed one of the
two primary researchers before commencing data col-
lection themselves.
Classification
Initial classification of each anomaly was conducted
by the researcher who collected the relevant data.
Anomalies about which the researchers were uncer-
tain, or which were potentially dispensing errors but
not explicitly considered by Franklin and O’Grady,2
were discussed and classified by consensus during
regular teleconferences attended by MR, SS, BDF,
NB, MB and TA. A cumulative list of all discussions
was produced, with classification decisions and princi-
ples recorded as a ‘case law’ document to ensure a
consistent approach throughout the study. For
example, it was agreed that if a prescriber specified an
indication on the prescription (such as omeprazole
‘for oesophagitis’), then omission of this indication
from the dispensing label was a labelling error.
Once the main anomaly category (content error,
labelling error, EPSR2-specific labelling error, label-
ling enhancement or EPSR2-specific intervention) was
decided, each anomaly was further categorised into
one of 16 mutually exclusive subcategories (see online
supplementary appendix 1), based on those used
Box 2 Definitions
A dispensing error was defined as any unintended devi-
ation from an interpretable written prescription or medi-
cation order. Any unintended deviation from professional
or regulatory references, or guidelines affecting dispens-
ing procedures, was also considered a dispensing error.
Dispensing a medication without a patient information
leaflet was not considered an error. Dispensing errors
were subdivided into content errors and labelling errors,
with EPSR2-specific labelling errors a further subcategory
of labelling error.
Content errors were those relating to the content
(ie, the dispensed item itself or any additional consum-
ables).
Labelling errors were those concerning the dispensing
label.
An EPSR2-specific labelling error was any labelling
error caused specifically by the different functionality of
the EPSR2 system, when compared with a non-EPSR2
prescription.
A labelling enhancement was any deviation from an
interpretable prescription, or from formal professional
guidance and practice, which communicates beneficial
information to the patient or caregiver (in addition to the
statutory requirements), facilitates proper storage of the
medicinal product provided, or enhances the dispensing
process.
An EPSR2-specific intervention was any intentional
modification of terminology between the prescriber’s
instructions on an EPSR2 prescription and that printed on
the dispensed item’s label, which was required specific-
ally as a result of EPSR2 functionality, in order to reason-
ably fulfil the prescription as intended.
EPSR2, Electronic Prescription Service Release 2.
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previously.2 Database restrictions meant that only one
anomaly of a given subcategory could be associated
with each dispensed item. Very rarely, two or more
anomalies with the same anomaly subcategory were
identified in the same dispensed item; the hierarchy in
figure 2 was then employed to determine which was
recorded. For example, a dispensing label with a
missing advisory label as well as an additional advan-
tageous label would, in theory, require two classifica-
tions: ‘labelling error’ and ‘enhancement’. However,
according to figure 2, a labelling error alone was
recorded.
Data entry and analysis
All data were entered into a MySQL database and
checked by SS and MR to identify and resolve any
inconsistencies in classification or data entry.
As well as descriptive analysis, two multivariable
mixed effects logistic regression models were fitted
for each outcome measure (labelling error, content
error and enhancement) to explore differences in the
prevalence of these outcome measures for EPSR2 in
comparison to non-EPSR2 items after adjusting for
pharmacy and time. The models were (1) EPSR2
versus non-EPSR2, adjusted for data collection visit
(random effect) and pharmacy (fixed effect) and (2)
EPSR2 versus non-EPSR2, adjusted for pharmacy
characteristics (independent, small chain, etc) and
location (inner city, suburbia, etc) as fixed effects, and
data collection visit and pharmacy (both random
effects). Both were two-level hierarchical models with
the relevant outcome measure at level 1 and pharmacy
at level 2, with non-EPSR2 items as the reference cat-
egory. Effects of model variables were presented as
ORs with associated 95% CIs; statistical significance
was set at p<0.05 (two-sided). Inter-rater reliability
for the two principal researchers’ assessment of 40
patients’ items was measured using Cohen’s κ.
Statistical analysis was conducted using STATA SE
V.11.2 (STATA Corp).
Ethics
This study was considered a service evaluation by the
Cambridgeshire I Research Ethics Committee,
reference 08/H0304/58. Individual researchers
obtained appropriate approvals from each local PCT;
permission to attend each community pharmacy was
given from the appropriate site lead. No patient-
identifiable data were recorded.
RESULTS
Overview
Nine pharmacies were approached and recruited ini-
tially, of which two were already using EPSR2 for a
small proportion of prescriptions when data collection
started. Two more went live with EPSR2 during our
study period; the remaining five did not. A further six
EPSR2-live pharmacies were subsequently approached
and recruited. None of the pharmacies approached
declined to take part. A total of 15 pharmacies were
therefore studied in total, from across five English
PCTs, using five different pharmacy computer
systems. A further PCTwas unable to assist with iden-
tifying pharmacies due to resource issues. All major
general practice and pharmacy computer systems used
in England were represented. Of the 15 pharmacies, 4
were from large national pharmacy chains, 8 were
from smaller local chains and 3 were independent.
Due to delays in national EPSR2 deployment, these
numbers were much lower than our target sample of
42 pharmacies; the proportion of EPSR2 prescriptions
in participating pharmacies was also lower than antici-
pated. We therefore conducted additional data collec-
tion visits in pharmacies wherever possible for the
duration of the study.
Data collection took place between November 2009
and September 2012, with a gap from October 2011
to February 2012 inclusive, while a year-long project
extension was negotiated to cover the delayed EPSR2
roll out. We conducted 95 data collection visits (mean
6.3 per pharmacy; range 3–11). The initial nine phar-
macies were visited a mean of 7.8 times each; the six
pharmacies recruited later were visited a mean of 4.2
times. We examined a total of 16 357 items prescribed
on 8242 prescriptions for 6409 patients (not necessar-
ily unique patients between data collection visits)
across all data collection visits, with a mean of 549
prescription forms per pharmacy (range 203–961)
and 172 items per visit.
Of the 16 357 dispensed items examined, about a
quarter were prescribed on computer-generated
non-EPS prescriptions (3654; 22%), 81 (0.5%) were
handwritten, just over half were on EPSR1 prescrip-
tions (8889 items; 54%), approximately a quarter
(3699; 23%) were on EPSR2 prescriptions with a
paper token, and 34 (0.2%) were on EPSR2 prescrip-
tions sent without a paper token. Overall, 3733 items
(23%) were therefore transmitted electronically.
Online supplementary appendix 2 presents the cumu-
lative numbers of EPSR2 and non-EPSR2 items exam-
ined during the study. The majority of items studied
Figure 2 Anomaly classification hierarchy (EPSR2, Electronic
Prescription Service Release 2).
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(91.7%) were already dispensed and awaiting collec-
tion: 8.3% were checked in real time.
Errors and enhancements
Overall, 885 (5.4%) of 16 357 items had a labelling
error, 222 (1.4%) had a content error, and 2225
(13.6%) had an enhancement made by the community
pharmacy staff. Of the 3733 EPSR2 items, an
EPSR2-specific intervention was made for a further
817 (21.9%) to amend the directions as entered by
the prescriber.
Types of labelling error are shown in table 1; these
most commonly involved dose instructions and add-
itional warning labels. There were 224 content errors
in 222 items; these most commonly involved not pro-
viding a suitable measuring device for liquid medi-
cines (124; 55%), or dispensing the wrong quantity of
medication (75; 33%). The latter generally involved
minor discrepancies between the label and the con-
tents, such as a box of 30 tablets dispensed against a
prescription for 28 tablets with a label stating 28
tablets. Enhancements made by community pharmacy
staff largely concerned additional ancillary labels (over
and above those recommended by the British National
Formulary), but also included additional information
included with the dose directions, or greater clarity in
relation to the name of the product. EPSR2-specific
interventions largely involved pharmacists translating
shorthand directions (that the GP had typed and
would appear verbatim on the dispensing label) into
more patient-friendly versions, such as ‘1BD’ changed
to ‘Take one tablet twice a day’; others involved chan-
ging the wording slightly to fit their preferred
professional style. Examples of errors, enhancements
and EPSR2-specific interventions are presented in box
3.
The two principal data collectors examined the
medication for 40 patients, comprising 85 dispensed
items. κ was 0.85 for whether or not items had one
or more errors, and 1.0 for whether or not there were
any other anomalies.
The effects of EPSR2
Labelling errors were more prevalent for items pre-
scribed on EPSR2 prescriptions, while the prevalence
of content errors and enhancements were similar
across all prescription types (table 2).
The higher prevalence of labelling errors associated
with EPSR2 prescriptions was due to errors of two
subcategories: dose instructions and additional
warning labels (table 1). The former mainly involved
one pharmacy, where local GPs were in the habit of
specifying the indication in the directions (eg, ‘One to
be taken every morning for high blood pressure’) but
this indication information was omitted from the dis-
pensed item (eg, the label would simply become ‘One
to be taken every morning’). The latter mostly
involved out-of-date or incorrect additional warning
labels, such as omeprazole capsules having an
unnecessary warning to swallow whole.
In relation to the multivariable analysis, model 2
would not converge because the covariates relating to
the pharmacy characteristics did not provide any add-
itional information from that already given by adjust-
ing for the pharmacy. Results from model 2 are
therefore not presented. Table 3 presents the results
obtained using model 1.
This analysis indicated a statistically significant 46%
increase (CI 21% to 76%) in labelling errors for
EPSR2 items compared to non-EPSR2. We inspected
the raw data to explore the cause of this difference
and found that the largest absolute and relative per-
centage increase was attributable to one specific type
of labelling error involving the omission of the indica-
tion, where specified by the prescriber, from the dis-
pensing label. We identified 158 of these, 155 of
which occurred at one pharmacy. While these
occurred for EPSR2 and non-EPSR2 prescriptions,
this pharmacy accounted for a relatively high propor-
tion (15%) of EPSR2 items studied. We therefore con-
ducted a sensitivity analysis, in which model 1 was
rerun with all 158 cases of this nature coded as not
being in error. This indicated no statistically signifi-
cant effect of EPSR2 on labelling errors (table 3).
DISCUSSION
Principal findings
Using an independent check of items dispensed in 15
English community pharmacies, we identified a label-
ling error in 5.4% of all items dispensed, and a
content error in 1.4%. We also present for the first
Table 1 Number of errors of each subcategory of labelling error
for non-EPSR2 and EPSR2 prescriptions
Type of labelling
error
Number of errors
identified in items
prescribed on
NON-EPSR2
prescriptions
(% of items)
Number of errors
identified in items
prescribed on
EPSR2
prescriptions
(% of items)
Patient name 82 (0.65) 2 (0.05)
Product name 63 (0.50) 8 (0.21)
Drug strength 5 (0.04) 0 (0.00)
Drug quantity 20 (0.16) 3 (0.08)
Dosage form 4 (0.03) 9 (0.24)
Dose instructions 168 (1.33) 140 (3.75)
Additional warning
labels
284 (2.25) 136 (3.64)
Dispensing date 3 (0.02) 0 (0.00)
Pharmacy address 0 (0.00) 0 (0.00)
Other labelling errors 135 (1.07) 50 (1.34)
TOTAL 764 348
Totals add to more than those in table 2 due to some items having more
than one labelling error.
EPSR2, Electronic Prescription Service Release 2.
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time the prevalence of labelling enhancements made
by community pharmacy staff to better communicate
information to the patient or caregiver or facilitate
proper storage of the product, made for 13.6% of
items. A further 21.9% of items dispensed from
EPSR2 prescriptions received intervention on the
part of community pharmacy staff to make the pre-
scriber’s electronically transmitted directions under-
standable, more patient-friendly and/or in line with
that pharmacy’s standard labelling format. When
comparing items prescribed on EPSR2 versus
non-EPSR2 prescriptions, we initially identified a
higher prevalence of labelling errors for the EPSR2
items, but no difference in the prevalence of content
errors or enhancements. The apparent increase in
labelling errors was largely accounted for by errors at
a single pharmacy in which the indication, where
specified by the prescriber, was not included on the
dispensing label. This occurred for EPSR2 and
non-EPSR2 items. While this style of labelling is in
line with good practice, these errors largely occurred
at one pharmacy which accounted for a relatively
high proportion of EPSR2 items, resulting in a dis-
proportionately large influence on the findings relat-
ing to EPSR2 prescriptions. A sensitivity analysis in
which these cases were not included as errors sug-
gested that there was no remaining difference in
labelling error rates.
Strengths and limitations
Strengths of our study include our large sample size,
and our use of a gold standard data collection method
involving examination of dispensed items by trained
researchers with a pharmacy background. We used
established methods and definitions, and a rigorous
approach to the classification of errors and enhance-
ments. Our study design is stronger than the
before-and-after design used in previous studies,11 as
each site acts as its own control. Limitations were that
participating pharmacies were neither randomly
selected nor allocated to order of adoption; they were
innovators that mainly served one GP practice, and
may not have been representative of other pharmacies.
As the roll out was markedly slower than expected we
recruited fewer sites than planned, conducting more
visits per site to compensate. Our researchers could
not be blinded to the type of prescription on which
each item was prescribed, and 17% of data were col-
lected by researchers for whom we did not test inter-
rater reliability.
Comparison with previous literature
We report a similar prevalence of content errors
(1.4% of dispensed items) to that of 1.7% published
previously in a UK study using the same methods and
definitions.2 However, the prevalence of labelling
errors was higher in our study, affecting 5.4% of
items in comparison with 1.6%.2 This was largely
accounted for by errors involving the omission of
medication indications, or use of additional warnings.
Our error rates are also in line with international
figures.1 5 Similar to previous qualitative studies,14 15
we also identified additional work required by
Box 3 Examples of errors, enhancements and
interventions
Dispensing errors
Content errors
▸ 10 mg busipirone tablets prescribed; Buscopan 10 mg
(hyoscine butylbromide) dispensed (labelled as for
busipirone)
▸ 56 lansoprazole 15 mg capsules prescribed; one box
of 28 dispensed in error
Labelling errors
▸ Sulfasalzine 500 mg enteric coated tablets prescribed
as ‘three to be taken twice daily’; labelled as ‘take
three daily’
▸ Aspirin dispensed without additional warning label
21 (‘take with or just after food, or a meal’) printed
on the label
EPSR2-specific labelling errors
▸ Co-dydramol 10/500 mg tablets prescribed with
instructions ‘1–2 tabs 4–6 hourly prn/max 8 daily’
which was then printed verbatim on the dispensing
label
▸ Azithromycin 200 mg/5 mL suspension prescribed
with instructions ‘take 3.25 mL (130 mg) on Monday,
Wednesday and Friday. Please issue one bottle con-
stituted and three bottles dry for mum to make up’
all of which was printed verbatim on the dispensing
label
Labelling enhancements
Additional ancillary labels
▸ Risedronate sodium 35 mg tablets—extra warnings
added: ‘swallow whole’, ‘take with plenty of water’,
‘avoid milk, iron, zinc or indigestion remedies at the
same time’ and ‘once a week dose’
▸ Simvastatin tables—extra warning added: ‘avoid con-
sumption of grapefruit’
Additional information in relation to dosing directions
▸ Naproxen 500 mg tablets—prescription stated ‘As
directed’. Labelled as ‘To be taken as directed by
your doctor—usually one to be taken twice a day’
▸ Citalopram 20 mg tablets—Prescription states ‘60 mg
od’. Labelled as ‘Three to be taken (60 mg) daily’
Additional information surrounding product name
▸ Prescribed warfarin 3 mg tablets—labelled as ‘war-
farin 3 mg (blue) tablets’
EPSR2-specific interventions
▸ Felodipine 10 mg MR (modified release) tablets pre-
scribed ‘1 OM’ (once daily in the morning) and
labelled as ‘one to be taken each morning’
EPSR2, Electronic Prescription Service Release 2.
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pharmacy staff to improve quality of electronic pre-
scriptions; in many cases community pharmacy staff
had to translate directions to make these more
patient-friendly.
Implications for practice
Our results suggest that one of the anticipated benefits
of EPSR2, a reduction in labelling errors, is not cur-
rently being realised; this is predominantly because of
prescribing practices and pharmacy computer systems.
Prescribers’ dosage instructions vary in quality,4 and
many prescriptions include dosage instructions that
are not written directly for the patient’s use.
Instructions keyed in by the GP, such as ‘1OD’ (one to
be taken daily), are automatically transferred by
EPSR2 to the dispensing label; an amendment then
has to be made manually by pharmacy staff, resulting
in errors if this is not done or done incorrectly. The
failure to write an appropriate instruction may reflect
the GP’s lack of knowledge of the consequences of
their action, lack of knowledge of how to enter a
quick prescribing code, poor usability of the software
system, or a combination of all three. We recommend
that community pharmacists, GPs, professional bodies
and software suppliers work together to agree how
items should be prescribed and labelled, how GP pre-
scribing software can support this, and how this
should best be communicated using EPSR2. Labelling
errors caused by the pharmacy computer system
usually involved the automatic inclusion of additional
warning labels that were out of date, either because
products had been reformulated, or because recom-
mendations had been revised. Our data suggest that
such problems were pharmacy-specific. Community
pharmacists need to be aware of how and when to
upgrade the databases used by their dispensing
systems, and suppliers need to make this easy to do.
The significant role of community pharmacy staff in
improving labelling instructions, additional to their
interventions involving contacting the prescriber,
patient or other healthcare professional,16 is an
important role which should be recognised.
Unanswered questions and future research
Future work should focus on how best to reap the
potential benefits concerned with the electronic trans-
mission of prescriptions. The severity of the errors
should be considered in future work.
CONCLUSION
The introduction of EPSR2 did not seem to affect
content errors nor, contrary to expectations, did it
seem to reduce labelling errors. Additional work was
required by pharmacy staff to improve the informa-
tion on medication labels, some of which was a result
of EPSR2. More than one in five items dispensed
from EPSR2 prescriptions received intervention on
the part of community pharmacy staff to make the
electronically transmitted directions more understand-
able and/or in line with local practice. Community
pharmacists and GPs need to work together to agree
how items should be dispensed and labelled in order
Table 2 Prevalence of dispensed items with one or more labelling error(s), content error(s), enhancement(s) and EPSR2-specific
intervention(s) for each type of prescription
Hand-written
n=81 (%)
Computer-generated
non-EPS
n=3654 (%)
EPSR1
n=8889
(%)
Total
non-EPSR2
n=12 624 (%)
EPSR2
n=3733
(%)
OVERALL
n=16 357
(%)
Content error 1 (1.2) 75 (2.1) 94 (1.1) 170 (1.3) 52 (1.4) 222 (1.4)
Labelling error (including EPSR2-specific
labelling error)
9 (11.1) 160 (4.4) 439 (4.9) 608 (4.8) 277 (7.4) 885 (5.4)
EPSR2-specific labelling error NA NA 0 0 16 (0.4) 16 (0.1)
Labelling enhancement 6 (7.4) 454 (12.4) 1232 (13.9) 1692 (13.4) 533 (14.3) 2225 (13.6)
EPSR2-specific intervention NA NA 0 0 817 (21.9) 817 (5.0)
EPSR2, Electronic Prescription Service Release 2.
Table 3 Results using multivariable model 1
Outcome measure OR (95% CI) p Value Goodness-of-fit (AIC)
Original analysis
Labelling errors (including EPSR2-specific labelling errors) 1.46 (1.21 to 1.76) <0.001 6485.15
Content error 1.16 (0.77 to 1.75) 0.467 2279.97
Enhancement 1.02 (0.90 to 1.16) 0.739 12600.59
Sensitivity analysis with 158 cases of missing indication recoded as not being in error
Labelling errors (including EPSR2-specific labelling errors) 1.04 (0.84 to 1.29) 0.720 5817.54
AIC, Akaike information criterion; EPSR2, Electronic Prescription Service Release 2.
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to best reap the benefits of EPSR2, and community
pharmacists need to ensure that their computer
systems are up to date. Community pharmacy staff
play a key additional role in quality and safety, making
enhancements to the labels of one in seven dispensed
items, whether transmitted using EPSR2 or otherwise,
to better communicate key information to the
recipient.
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